GH
Guardant Health, Inc.
$125.61
-5.60%
$16.7B
No data for this timeframe.
Vol
Market Cap$16.7B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders9 funds
Inst. Value$2.3B
Inst. Activity3 buys / 0 sells
Insider Activity0B / 13S
Insider Net $-$12.8M
Reddit Sentiment67° Warm
SEC Reports14
Recent Activity
Jun 5, 2026
SEC
Three Guardant Health directors sold a total of $1.81M in open-market sales over a 7-day window, with the largest sale (
CLUSTER — Impact 3/10
Jun 5, 2026
SEC
Craig Eagle, a former affiliate of Guardant Health, filed a Form 144 notice of intent to sell 160,817 shares of common s
144 — Impact 5/10
Jun 4, 2026
SEC
Two Guardant Health insiders — the Chief Legal Officer and a Director — sold a combined $1.38M in open-market sales over
CLUSTER — Impact 3/10
Jun 4, 2026
Insider
Krognes Steve E. sold 9,294 shares
Director @ $132.51 ($1.2M)
Jun 3, 2026
Insider
Joyce Meghan V. sold 1,197 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Joyce Meghan V. sold 3,516 shares
Director @ $126.52 ($444.8K)
Inst.
FMR LLC — DOUBLED
2,396,433 shares ($244.8M)
Inst.
NORGES BANK — NEW
1,258,072 shares ($128.5M)
Price Targets
$137.09
+9.1% upside
Buy
Current $125.61
Low $90.00
Median $135.00
High $190.00
22 analysts
$90.00
$190.00
Analyst Ratings
14Strong Buy
15Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 5, 2026 | Goldman Sachs | INITIATE | Buy → Buy |
| Jun 2, 2026 | Evercore ISI Group | UPGRADE | In-Line → Outperform |
| May 27, 2026 | BTIG | MAINTAIN | Buy → Buy |
| May 26, 2026 | BTIG | MAINTAIN | Buy → Buy |
| May 8, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next FY | $-0.57 ▲ +17.5% | $-1.92 — $0.64 | 60% YoY | 17 |
| Current Q | $-0.40 | $-0.60 — $-0.21 | 10% YoY | 16 |
| Next Q | $-0.30 ▲ +11.2% | $-0.36 — $-0.26 | 23% YoY | 16 |
| Current FY | $-1.42 ▲ +9.5% | $-1.76 — $-1.25 | 22% YoY | 17 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Three Guardant Health directors sold a total of $1.81M in open-market sales over a 7-day window, with the largest sale (
Jun 5, 2026
BEARISH
144
5/10
Craig Eagle, a former affiliate of Guardant Health, filed a Form 144 notice of intent to sell 160,817 shares of common s
Jun 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.2B | — |
| FMR LLC | $244.8M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $222.2M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $148.9M | ADD |
| NORGES BANK | $128.5M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Krognes Steve | SELL | $1.2M |
| Jun 3, 2026 | Joyce Meghan | M | $0.00 |
| Jun 3, 2026 | Joyce Meghan | SELL | $444.8K |
| Jun 3, 2026 | Joyce Meghan | M | $46.0K |
| May 31, 2026 | Krognes Steve | M | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
9 institutional holders with $2.3B total value (22,437,274 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, TWO. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 12,160,768 | $1.2B | 54.2% | — |
| 2 | FMR LLC | 2,396,433 | $244.8M | 10.7% | DOUBLED +190.7% |
| 3 | TWO SIGMA INVESTMENTS, LP | 2,175,903 | $222.2M | 9.7% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,457,676 | $148.9M | 6.5% | ADD +39.7% |
| 5 | NORGES BANK | 1,258,072 | $128.5M | 5.6% | NEW |
| 6 | MORGAN STANLEY | 1,154,299 | $117.9M | 5.1% | TRIM -34.3% |
| 7 | BANK OF AMERICA CORP /DE/ | 1,017,646 | $103.9M | 4.5% | ADD +45.4% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 602,300 | $61.5M | 2.7% | — |
| 9 | WELLS FARGO & COMPANY/MN | 214,177 | $21.9M | 1.0% | ADD +87.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 824,265 | 2,396,433 | +190.7% | $244.8M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,258,072 | — | $128.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 113,985 | 214,177 | +87.9% | $21.9M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,013,272 | 1,415,884 | +39.7% | $88.5M | 2025-Q3 |
| NORGES BANK | EXIT | 1,232,428 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 1,232,428 | — | $64.1M | 2025-Q2 |
| UBS Group AG | TRIM | 2,281,061 | 1,219,019 | -46.6% | $63.4M | 2025-Q2 |
| FMR LLC | DOUBLED | 489,929 | 987,675 | +101.6% | $51.4M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 486,365 | 707,404 | +45.4% | $36.8M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 177,004 | 119,952 | -32.2% | $6.2M | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 1,702,989 | 3,857,113 | +126.5% | $164.3M | 2025-Q1 |
| UBS Group AG | ADD | 1,755,391 | 2,281,061 | +29.9% | $97.2M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,432,416 | 940,505 | -34.3% | $40.1M | 2025-Q1 |
| FMR LLC | TRIM | 1,159,611 | 489,929 | -57.8% | $20.9M | 2025-Q1 |
| NORGES BANK | EXIT | 1,192,742 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 361,067 | 1,755,391 | +386.2% | $53.6M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 554,901 | 1,702,989 | +206.9% | $52.0M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 77,689 | 167,929 | +116.2% | $5.1M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,003,138 | — | $23.0M | 2024-Q3 |
14 unique insiders with 13 transactions. Net insider value: -$12.8M ($0.00 bought, $12.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Krognes Steve E. | Director | SELL | 9,294 | $132.51 | $1.2M |
| Jun 3, 2026 | Joyce Meghan V. | Director | M | 1,197 | $0.00 | $0.00 |
| Jun 3, 2026 | Joyce Meghan V. | Director | SELL | 3,516 | $126.52 | $444.8K |
| Jun 3, 2026 | Joyce Meghan V. | Director | M | 1,197 | $38.42 | $46.0K |
| May 31, 2026 | Krognes Steve E. | Director | M | 154 | $0.00 | $0.00 |
| May 31, 2026 | Krognes Steve E. | Director | M | 154 | $0.00 | $0.00 |
| May 28, 2026 | Hidalgo Medina Manuel | Director | SELL | 1,000 | $130.06 | $130.1K |
| May 27, 2026 | Saia John G. | Chief Legal Officer | SELL | 9,994 | $125.08 | $1.3M |
| May 22, 2026 | Freeman Chris | Chief Commercial Officer | SELL | 24,406 | $118.67 | $2.9M |
| May 22, 2026 | Freeman Chris | Chief Commercial Officer | M | 24,406 | $32.86 | $802.0K |
| May 22, 2026 | Freeman Chris | Chief Commercial Officer | M | 24,406 | $0.00 | $0.00 |
| May 20, 2026 | Hidalgo Medina Manuel | Director | M | 1,000 | $32.55 | $32.5K |
| May 20, 2026 | Hidalgo Medina Manuel | Director | SELL | 1,000 | $107.10 | $107.1K |
| May 20, 2026 | Hidalgo Medina Manuel | Director | M | 1,000 | $0.00 | $0.00 |
| May 20, 2026 | CLARK IAN T | Director | SELL | 6,876 | $106.90 | $735.0K |
| May 20, 2026 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 200 | $100.95 | $20.2K |
| May 20, 2026 | Saia John G. | Chief Legal Officer | SELL | 5,632 | $105.34 | $593.3K |
| May 18, 2026 | Tariq Musa | Director | SELL | 116 | $95.96 | $11.1K |
| May 17, 2026 | Hidalgo Medina Manuel | Director | M | 232 | $0.00 | $0.00 |
| May 17, 2026 | Hidalgo Medina Manuel | Director | M | 232 | $0.00 | $0.00 |
| May 15, 2026 | Chudova Darya | Chief Technology Officer | M | 8,705 | $0.00 | $0.00 |
| May 15, 2026 | Chudova Darya | Chief Technology Officer | F | 4,679 | $94.92 | $444.1K |
| May 15, 2026 | Chudova Darya | Chief Technology Officer | M | 8,705 | $0.00 | $0.00 |
| May 15, 2026 | Tariq Musa | Director | M | 250 | $0.00 | $0.00 |
| May 15, 2026 | Tariq Musa | Director | M | 250 | $0.00 | $0.00 |
| May 12, 2026 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 50,000 | $100.32 | $5.0M |
| Apr 30, 2026 | Krognes Steve E. | Director | M | 154 | $0.00 | $0.00 |
| Apr 30, 2026 | Krognes Steve E. | Director | M | 154 | $0.00 | $0.00 |
| Apr 21, 2026 | MIGNONE ROBERTO | Director | M | 264 | $0.00 | $0.00 |
| Apr 21, 2026 | MIGNONE ROBERTO | Director | M | 264 | $0.00 | $0.00 |
| Apr 17, 2026 | Hidalgo Medina Manuel | Director | M | 232 | $0.00 | $0.00 |
| Apr 17, 2026 | Hidalgo Medina Manuel | Director | M | 232 | $0.00 | $0.00 |
| Apr 16, 2026 | Tariq Musa | Director | SELL | 116 | $84.83 | $9.8K |
| Apr 15, 2026 | Saia John G. | Chief Legal Officer | M | 7,569 | $0.00 | $0.00 |
| Apr 15, 2026 | Saia John G. | Chief Legal Officer | F | 3,970 | $84.86 | $336.9K |
| Apr 15, 2026 | Saia John G. | Chief Legal Officer | M | 7,569 | $0.00 | $0.00 |
| Apr 15, 2026 | Tariq Musa | Director | M | 250 | $0.00 | $0.00 |
| Apr 15, 2026 | Tariq Musa | Director | M | 250 | $0.00 | $0.00 |
| Apr 6, 2026 | Monroe Terilyn J. | Chief People Officer | SELL | 3,832 | $92.68 | $355.1K |
| Apr 1, 2026 | Bell Michael Brian | Chief Financial Officer | M | 2,084 | $0.00 | $0.00 |
| Apr 1, 2026 | Bell Michael Brian | Chief Financial Officer | M | 2,084 | $0.00 | $0.00 |
| Apr 1, 2026 | Chudova Darya | Chief Technology Officer | F | 7,005 | $91.15 | $638.5K |
| Apr 1, 2026 | EAGLE CRAIG | Chief Medical Officer | F | 5,779 | $91.15 | $526.8K |
| Apr 1, 2026 | EAGLE CRAIG | Chief Medical Officer | M | 1,714 | $0.00 | $0.00 |
| Apr 1, 2026 | Freeman Chris | Chief Commercial Officer | M | 1,929 | $0.00 | $0.00 |
| Apr 1, 2026 | Freeman Chris | Chief Commercial Officer | F | 4,750 | $91.15 | $433.0K |
| Apr 1, 2026 | Freeman Chris | Chief Commercial Officer | M | 1,929 | $0.00 | $0.00 |
| Apr 1, 2026 | Kalia Kumud | Chief Information Officer | M | 1,607 | $0.00 | $0.00 |
| Apr 1, 2026 | Kalia Kumud | Chief Information Officer | F | 5,092 | $91.15 | $464.1K |
| Apr 1, 2026 | Kalia Kumud | Chief Information Officer | M | 1,607 | $0.00 | $0.00 |
14 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 11 neutral. Avg impact: 3.2/10.
NEUTRAL
CLUSTER
3/10
Three Guardant Health directors sold a total of $1.81M in open-market sales over a 7-day window, wit
Jun 5, 2026
BEARISH
144
5/10
Craig Eagle, a former affiliate of Guardant Health, filed a Form 144 notice of intent to sell 160,81
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
Two Guardant Health insiders — the Chief Legal Officer and a Director — sold a combined $1.38M in op
Jun 4, 2026
NEUTRAL
CLUSTER
2/10
Two Guardant Health insiders sold a combined $1.38M in open-market sales over two days, led by the C
Jun 1, 2026
NEUTRAL
CLUSTER
3/10
Three Guardant Health insiders, including the Chief Legal Officer and Chief Commercial Officer, sold
May 29, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider sales at Guardant Health totaling $5.01M over a 7-day window, led by the Chief
May 28, 2026
BULLISH
COURT-RULING
6/10
The Court adopted Guardant Health's proposed construction for the key claim term "location on a [ref
May 28, 2026
NEUTRAL
CLUSTER
2/10
Six Guardant Health insiders sold a total of $4.36M in open-market sales over a 7-day window, led by
May 26, 2026
NEUTRAL
CLUSTER
2/10
Five Guardant Health insiders, including the CEO and CLO, sold a total of $1.47M in open-market sale
May 22, 2026
NEUTRAL
CLUSTER
2/10
Three Guardant Health directors sold a total of ~$853K in open-market sales over a 7-day window, wit
May 22, 2026
BEARISH
144
6/10
Co-founder and CEO AmirAli Talasaz filed a Form 144 to sell 260,000 shares of Guardant Health common
May 12, 2026
NEUTRAL
DEFA14A
2/10
Guardant Health filed additional definitive proxy materials for its 2026 annual meeting, reminding s
Apr 28, 2026
NEUTRAL
8-K
3/10
Guardant Health announced the resignation of Chief Medical Officer Dr. Craig Eagle, effective May 8,
Apr 27, 2026
NEUTRAL
CLUSTER
3/10
A recent insider trading cluster at Guardant Health shows multiple non-cash derivative exercises and
Mar 23, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (91% buy). Based on 32 analysts: 14 strong buy, 15 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$137.09 mean target
+9.1% upside
Buy (1.30)
$90.00 Low
$190.00 High
| Metric | Value |
|---|---|
| Current Price | $125.61 |
| Target Low | $90.00 |
| Target Mean | $137.09 |
| Target Median | $135.00 |
| Target High | $190.00 |
| # Analysts | 22 |
| Recommendation | Buy (1.30) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next FY 2027-12-31 |
$-0.57 | $-1.92 | $0.64 | 59.8% | +17.5% | 8↑ 6↓ | $1.7B | 29.0% | 17 |
| Current Q 2026-06-30 |
$-0.40 | $-0.60 | $-0.21 | 9.9% | -0.1% | 7↑ 6↓ | $0.3B | 35.3% | 16 |
| Next Q 2026-09-30 |
$-0.30 | $-0.36 | $-0.26 | 23.1% | +11.2% | 10↑ 3↓ | $0.3B | 27.9% | 16 |
| Current FY 2026-12-31 |
$-1.42 | $-1.76 | $-1.25 | 22.0% | +9.5% | 12↑ 2↓ | $1.3B | 33.8% | 17 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.396 | |
| 7d ago | $-0.391 | -0.005 |
| 30d ago | $-0.396 | -0.000 |
| 60d ago | $-0.397 | +0.000 |
| 90d ago | $-0.397 | +0.000 |
18 analyst firms have rated this stock: 2 upgrades, 1 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 5, 2026 | Goldman Sachs | INITIATE | Buy | Buy |
| Jun 2, 2026 | Evercore ISI Group | UPGRADE | In-Line | Outperform |
| May 27, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 26, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 8, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 8, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 8, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Apr 14, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Feb 24, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 20, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Feb 20, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 20, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 20, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Feb 20, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 17, 2026 | Baird | INITIATE | — | Outperform |
| Jan 26, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Evercore ISI Group | DOWNGRADE | Outperform | In-Line |
| Jan 5, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Dec 15, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Dec 12, 2025 | BTIG | MAINTAIN | Buy | Buy |
| Dec 11, 2025 | Citigroup | MAINTAIN | Buy | Buy |
| Dec 2, 2025 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Oct 30, 2025 | UBS | MAINTAIN | Buy | Buy |
| Oct 30, 2025 | Citigroup | MAINTAIN | Buy | Buy |
| Oct 30, 2025 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Oct 30, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Oct 30, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Oct 30, 2025 | BTIG | MAINTAIN | Buy | Buy |
| Oct 22, 2025 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Oct 7, 2025 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Oct 2, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Sep 26, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Sep 25, 2025 | TD Cowen | MAINTAIN | Buy | Buy |
| Sep 25, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Sep 25, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Sep 25, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Sep 25, 2025 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Sep 25, 2025 | UBS | MAINTAIN | Buy | Buy |
| Sep 25, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 14 | 15 | 3 | 0 | 0 | 91% | |
| May 1, 2026 | 14 | 15 | 4 | 0 | 0 | 88% | |
| Apr 1, 2026 | 14 | 16 | 4 | 0 | 0 | 88% | |
| Mar 1, 2026 | 14 | 16 | 4 | 0 | 0 | 88% | |
| Feb 1, 2026 | 12 | 17 | 3 | 0 | 0 | 91% | |
| Jan 1, 2026 | 13 | 17 | 3 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
GH!
▲ 1
💬 0
⚡ 0.5
May 27, 2026
Enforcement
Cold Spring Harbor Laboratory v. Guardant Health, Inc.
Court ruling from District Court, D. Delaware. Docket: 1:25-cv-00263
May 21, 2026
short_volume
Short Volume: GH — 58.4% short (1.2M / 2.1M)
Short: 1,217,696 | Exempt: 88,664 | TRF Vol: 2,083,568 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: GH — 71.5% short (0.5M / 0.7M)
Short: 500,924 | Exempt: 23,506 | TRF Vol: 700,217 | Short Ratio: 71.5% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: GH — 57.4% short (0.3M / 0.5M)
Short: 306,285 | Exempt: 15,956 | TRF Vol: 534,043 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: GH — 64.2% short (0.4M / 0.6M)
Short: 397,732 | Exempt: 376 | TRF Vol: 619,894 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: GH — 65,529 shares ($6.5M) failed to deliver
Settlement: 20260513, Price: $99.94, FTD Value: $6,548,968.26, GUARDANT HEALTH INC COM
May 12, 2026
short_volume
Short Volume: GH — 62.6% short (0.6M / 0.9M)
Short: 583,009 | Exempt: 13,400 | TRF Vol: 931,156 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: GH — 63.5% short (0.5M / 0.8M)
Short: 514,311 | Exempt: 25 | TRF Vol: 810,326 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: GH — 60.4% short (0.7M / 1.2M)
Short: 747,170 | Exempt: 5 | TRF Vol: 1,236,055 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
GH Q1 2026 Earnings After Market Close — 2026-05-07
May 5, 2026
short_volume
Short Volume: GH — 68.5% short (0.4M / 0.6M)
Short: 379,016 | Exempt: 4 | TRF Vol: 553,182 | Short Ratio: 68.5% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: GH — 71.6% short (0.4M / 0.6M)
Short: 410,792 | Exempt: 52 | TRF Vol: 573,831 | Short Ratio: 71.6% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
short_volume
Short Volume: GH — 56.9% short (0.7M / 1.2M)
Short: 694,398 | Exempt: 8 | TRF Vol: 1,219,560 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: GH — 60.5% short (0.7M / 1.2M)
Short: 720,169 | Exempt: 66,523 | TRF Vol: 1,190,695 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: GH — 64.6% short (0.4M / 0.6M)
Short: 392,248 | Exempt: 156 | TRF Vol: 607,658 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: GH — 58.3% short (0.3M / 0.5M)
Short: 302,172 | Exempt: 31,917 | TRF Vol: 518,175 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)